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It was with great interest that we read the results 
presented by Professors La-He Jearn and Th  ink-You  Kim 
regarding the inﬂ   uence of anti-cyclic citrullinated 
peptide (CCP) on anticentromere antibody (ACA)-
positive patients suﬀ   er  ing from rheumatoid arthritis 
(RA) [1]. Th  eir ﬁ   ndings explore the eﬀ   ect of ACA 
positivity in a patient group diﬀ  erent from the cohort of 
primary Sjögren syndrome (SS) patients we chose to 
study [2]. Due to the diﬀ  erent study population and the 
retrospective nature of our work, our data do not include 
measurement of anti-CCP antibodies. Anti-CCP anti-
bodies provide a speciﬁ  c tool for the diagnosis of RA that 
seems to correlate with disease severity and early erosive 
disease. Th  e method has a 70% sensitivity for RA [3], 
which is consistent with the 70.6% positivity of anti-CCP 
reported by Jearn and Kim among their ACA-positive 
RA group. A striking point in the results presented by the 
two colleagues is the high prevalence (21%) of RA among 
ACA-positive patients, which is not in line with previous 
publications that have reported a prevalence of 5 to 6% 
[4]. In a general population of RA patients with variable 
antibody background, interstitial lung disease and 
Raynaud’s phenomenon have a reported prevalence in 
the range of 7.7 to 10% [5]. Jearn and Kim found 4 (11.8%) 
patients with interstitial lung disease and 1 (10%) patient 
with Raynaud’s phenomenon out of 34 ACA-positive RA 
patients. Despite the fact that the numbers are small and 
do not allow for safe conclusions, both results are well in 
the range reported in the literature for unselected RA 
patients and unrelated to the anti-CCP positivity. Th  is 
could, in a sense, indicate that the presence of ACA or 
anti-CCP antibodies in RA does not aﬀ  ect the clinical 
features in question. We believe that an extended 
presentation of the results found by Jearn and Kim would 
be very interesting and more than welcome. We also 
think that evaluation of our ACA-positive SS patients for 
anti-CCP reactivity should be interesting.
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